Yoshindo
Biosimilar developer, Japan. 1 development product across 1 molecule: ustekinumab.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab | Ustekinumab BS YD | · | · | · | Dec 2024 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Yoshindo is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Etanercept | Etanercept BS TY / Nichiiko | PMDA | Yoshindo; Nichi-Iko Pharmaceutical | Mar 2019 | Lupin |
Companies on the same molecules
Developers whose portfolios overlap most with Yoshindo, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- PMDADec 2024Ustekinumab BS YD, ustekinumab
Compare Yoshindo with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant